← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
P2d, Inc.
Cincinnati, OH
$20,878,595
Total funding
40
Grants
Funding over time
peak $3.4M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$20,878,595 · 40
By mechanism
R44$9,199,716 · 7
R43$8,807,597 · 29
SB1$1,647,446 · 1
R42$699,155 · 1
R41$524,681 · 2
Investigators at P2d, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Human Antibody as an Immunotherapy for Cocaine Abuse$922,721
R44 · FY2008 · DA
A Human Antibody as an Immunotherapy for Cocaine Abuse$911,120
R44 · FY2007 · DA
Phase 2 Selective DAT inhibitor for treatment of Obesity.$766,488
R44 · FY2011 · DK
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.$745,321
R44 · FY2015 · AG
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.$744,572
R44 · FY2016 · AG
Phase 2 Selective DAT inhibitor for treatment of Obesity.$740,782
R44 · FY2012 · DK
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment$696,900
SB1 · FY2017 · AG
LIVERCHIP - A diagnostic tool for genetic liver diseases$617,897
R44 · FY2014 · DK
ADHD Therapeutic: PD2005 DA Transport Inhibitor$599,030
R44 · FY2012 · MH
LIVERCHIP - A diagnostic tool for genetic liver diseases$560,619
R44 · FY2015 · DK
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment$534,299
SB1 · FY2018 · AG
ADHD Therapeutic: PD2005 DA Transport Inhibitor$480,803
R44 · FY2011 · MH
A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD$470,041
R44 · FY2021 · AG
Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder$469,495
R43 · FY2009 · MH
A Human Antibody as an Immunotherapy for Cocaine Abuse$444,299
R44 · FY2006 · DA
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment$416,247
SB1 · FY2019 · AG
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD$395,476
R43 · FY2013 · AG
A Novel Small molecule TNF?? inhibitor as a disease-modifying AD drug treatment.$390,959
R43 · FY2012 · AG
Improving hematopoietic stem cell mobilization by the EGFR inhibitor Erlotinib$390,255
R43 · FY2012 · HL
A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD$374,169
R44 · FY2022 · AG